福建沿海地区部分人群BMI与血清PGⅠ及PGⅠ/PGⅡ比值的相关性研究

doi:10.3969/j.issn.1673-8640.2015.08.007

摘要/Abstract

摘要：

目的探讨体重指数(BMI)对血清胃蛋白酶原Ⅰ(PGⅠ)水平和PGⅠ/胃蛋白酶原Ⅱ(PGⅡ)比值的影响。方法回顾性分析2 849名表观健康体检者的临床资料,根据《中国成人超重和肥胖症预防控制指南》将BMI划分为4个级别:体重过低(<18.5 kg/m²)、体重正常(18.5~23.9 kg/m²)、超重(24.0~27.9 kg/m²)及肥胖(≥28.0 kg/m²)。比较各组间临床资料、PGⅠ水平及PGⅠ/PGⅡ比值的差异,探论BMI变化与PGⅠ、PGⅠ/PGⅡ比值的关系。结果单因素分析显示体重过低组、超重组和肥胖组血清PGⅠ水平明显低于体重正常组(P值分别为0.022、0.024和0.008),而PGⅠ/PGⅡ比值在BMI各组间差异无统计学意义(P>0.05)。调整性别、年龄、血脂等混杂变量后,PGⅠ与BMI呈明显负相关(β=-1.232,P<0.001)。二分类Logistic回归分析显示肥胖是低PGⅠ水平(<70 μg/L)的相对独立危险因素之一(OR=1.682,P=0.001)。结论福建沿海地区部分人群血清低PGⅠ水平可能与肥胖有关。

中图分类号:

R446.1

许文燊, 林升, 陈惠娟, 詹富国, 刘灿, 欧启水, 陈静. 福建沿海地区部分人群BMI与血清PGⅠ及PGⅠ/PGⅡ比值的相关性研究[J]. 检验医学, 2015, 30(8): 804-807.

图/表 4

参考文献 18

[1]	ZHENG W,MCLERRAN DF,ROLLAND B,et al.Association between body-mass index and risk of death in more than 1 million Asians[J].N Engl J Med,2011,364(8) :719-729.
[2]	RENEHAN AG,TYSON M,EGGER M,et al.Body-mass index and incidence of cancer:a systematic review and meta-analysis of prospective observational studies[J]. Lancet,2008,371(9612) :569-578.
[3]	YANG P,ZHOU Y,CHEN B,et al.Overweight,obesity and gastric cancer risk:results from a meta-analysis of cohort studies[J]. Eur J Cancer,2009,45(16):2867-2873.
[4]	张金锋. 血清胃蛋白酶原、CEA、CA19-9及CA72-4检测对胃癌的诊断价值探讨[J]. 检验医学,2014,29(8):831-834.
[5]	邬建民,张力. 血清胃蛋白酶原、胃泌素-17和幽门螺杆菌IgG抗体对萎缩性胃炎的诊断价值[J]. 检验医学,2011,26(6):375-378.
[6]	FOCK KM,TALLEY N,MOAYYEDI P,et al.Asia-Pacific consensus guidelines on gastric cancer prevention[J]. J Gastroenterol Hepatol,2008,23(3):351-365.
[7]	ZHENG KC,AOKI K,LI XQ,et al.Serum pepsinogens,gastrin-17 and Helicobacter pylori antibody in the residents of two cities in china with distinct mortality rates of gastric cancer[J]. Tohoku J Exp Med,2012,228(4):289-294.
[8]	HUANG M,TANG AG,MU S,et al.Serum pepsinogen reference intervals in apparently healthy Chinese population with latex enhanced turbidimetric immuno-assay[J]. J Clin Pathol,2014,67(4):350-354.
[9]	ZHANG XM,LI JX,ZHANG GY,et al.The value of serum pepsinogen levels for the diagnosis of gastric diseases in Chinese Han people in midsouth China[J]. BMC Gastroenterol,2014,14:3.
[10]	CSENDES A,BURGOS AM,SMOK G,et al.Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity[J]. Obes Surg,2007,17(1):28-34.
[11]	GAO L,WECK MN,ROTHENBACHER D, et al.Body mass index,chronic atrophic gastritis and heartburn:a population-based study among 8 936 older adults from Germany[J]. Aliment Pharmacol Ther,2010,32(2):296-302.
[12]	YAMAMOTO S,WATABE K,TSUTSUI S,et al.Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis[J]. Dig Dis Sci,2011,56(8):2354-2360.
[13]	EL-HAGGAR SM, MOSTAFA TM.Adipokines and biochemical changes in Egyptian obese subjects: possible variation with sex and degree of obesity[J]. Endocrine, 2015, 48(3): 878-885.
[14]	AL-HAMODI Z, AL-HABORI M, AL-MEERI A, et al.Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus[J]. Diabetol Metab Syndr, 2014,6(1): 99.
[15]	TORISU T,MATSUMOTO T,TAKATA Y,et al.Atrophic gastritis,but not antibody to Helicobacter pylori,is associated with body mass index in a Japanese population[J]. J Gastroenterol,2008,43(10):762-766.
[16]	WATABE H,MITSUSHIMA T,DERAKHSHAN MH,et al.Study of association between atrophic gastritis and body mass index:a cross-sectional study in 10 197 Japanese subjects[J]. Dig Dis Sci,2009,54(5):988-995.
[17]	KUTSUMA A,OSHIDA H,SUWA K,et al.A possible association of low pepsinogen I and pepsinogen Ⅰ/Ⅱ with low and high body weight in Japanese men[J]. Clin Biochem,2014,47(1-2):126-128.
[18]	TANAKA M,FUKUI M,KURODA M,et al.Pepsinogen Ⅰ/Ⅱ ratio is related to glucose,triacylglycerol,and uric acid levels[J].Nutrition,2012,28(4):418-421.

组别	例数(%)		年龄(岁)	男性例数(%)		高血压[例(%)]		TC(mmol/L)
体重过低组	169	(5.93)	39.0±16.4	61(39.1)		11	(6.5)	4.87±0.90
体重正常组	1 491	(52.3)	47.8±13.9	700(46.9)		229	(15.4)	5.19±0.98
超重组	972	(34.1)	51.2±13.2^**	666(68.5)^**		266	(27.4)^**	5.37±0.99^**
肥胖组	217	(7.62)	50.4±14.9^**	142(65.4)^**		86	(39.6)^**	5.45±1.09^**
合计	2 849		48.6±14.2	1 569(55.1)		592	(20.8)	5.25±1.00
组别	TG(mmol/L)		Glu(mmol/L)	UA(μmol/L)			PGⅠ(μg/L)
体重过低组	0.87±0.48		5.02±1.92	292.0±81.3			101.93±45.12^*
体重正常组	1.22±0.87		5.21±1.21	322.0±82.7			110.51±50.10
超重组	1.69±1.05^**		5.47±1.43^**	378.0±89.9^**			106.14±44.96^*
肥胖组	2.13±1.96^**		5.86±1.91^**	394.0±88.8^**			100.93±45.49^*
合计	1.43±1.08		5.34±1.37	345.0±91.1			107.80±47.90
组别	PGⅡ (μg/L)		PGⅠ/PGⅡ 比值	用药史 [例(%)]			既往史[例(%)]
组别	PGⅡ (μg/L)		PGⅠ/PGⅡ 比值	用药史 [例(%)]			消化道溃疡		胃炎
体重过低组	13.24±8.66		9.50±4.42	5	(3.0)		3(2.0)		16(9.4)
体重正常组	13.72±9.70		9.81±4.19	115	(7.8)		30(2.0)		112(7.5)
超重组	12.74±8.48		10.19±4.64	148	(15.2)^**		17(1.7)		62(6.6)
肥胖组	12.15±8.13		10.08±4.42	35	(16.1)^**		2(0.9)		6(2.8)
合计	13.24±9.13		9.95±4.38	303	(10.6)		52(1.8)		196(6.9)

组别	例数(%)		年龄(岁)	男性例数(%)		高血压[例(%)]		TC(mmol/L)
体重过低组	169	(5.93)	39.0±16.4	61(39.1)		11	(6.5)	4.87±0.90
体重正常组	1 491	(52.3)	47.8±13.9	700(46.9)		229	(15.4)	5.19±0.98
超重组	972	(34.1)	51.2±13.2^**	666(68.5)^**		266	(27.4)^**	5.37±0.99^**
肥胖组	217	(7.62)	50.4±14.9^**	142(65.4)^**		86	(39.6)^**	5.45±1.09^**
合计	2 849		48.6±14.2	1 569(55.1)		592	(20.8)	5.25±1.00
组别	TG(mmol/L)		Glu(mmol/L)	UA(μmol/L)			PGⅠ(μg/L)
体重过低组	0.87±0.48		5.02±1.92	292.0±81.3			101.93±45.12^*
体重正常组	1.22±0.87		5.21±1.21	322.0±82.7			110.51±50.10
超重组	1.69±1.05^**		5.47±1.43^**	378.0±89.9^**			106.14±44.96^*
肥胖组	2.13±1.96^**		5.86±1.91^**	394.0±88.8^**			100.93±45.49^*
合计	1.43±1.08		5.34±1.37	345.0±91.1			107.80±47.90
组别	PGⅡ (μg/L)		PGⅠ/PGⅡ 比值	用药史 [例(%)]			既往史[例(%)]
组别	PGⅡ (μg/L)		PGⅠ/PGⅡ 比值	用药史 [例(%)]			消化道溃疡		胃炎
体重过低组	13.24±8.66		9.50±4.42	5	(3.0)		3(2.0)		16(9.4)
体重正常组	13.72±9.70		9.81±4.19	115	(7.8)		30(2.0)		112(7.5)
超重组	12.74±8.48		10.19±4.64	148	(15.2)^**		17(1.7)		62(6.6)
肥胖组	12.15±8.13		10.08±4.42	35	(16.1)^**		2(0.9)		6(2.8)
合计	13.24±9.13		9.95±4.38	303	(10.6)		52(1.8)		196(6.9)

变量	PGⅠ			PGⅠ/PGⅡ比值
变量	β值	Beta	P值	β值	Beta	P值
性别(男)	-15.028	-0.156	<0.001	-0.937	-0.106	<0.001
年龄	0.552	0.164	<0.001	-0.056	-0.182	<0.001
BMI	-1.232	-0.083	<0.001	0.180	0.032	0.114
高血压	-4.650	-0.039	0.047	-0.202	-0.020	0.337
Glu	0.166	0.005	0.806	0.155	0.049	0.011
TC	1.291	0.027	0.154	-0.027	-0.007	0.729
TG	0.055	0.002	0.909	0.180	0.044	0.020
UA	0.003	0.007	0.777	0.00	-0.017	0.481
药物史	2.590	0.017	0.410	0.721	0.048	0.009
既往史	2.728	0.017	0.366	0.702	0.049	0.012

变量	PGⅠ			PGⅠ/PGⅡ比值
变量	β值	Beta	P值	β值	Beta	P值
性别(男)	-15.028	-0.156	<0.001	-0.937	-0.106	<0.001
年龄	0.552	0.164	<0.001	-0.056	-0.182	<0.001
BMI	-1.232	-0.083	<0.001	0.180	0.032	0.114
高血压	-4.650	-0.039	0.047	-0.202	-0.020	0.337
Glu	0.166	0.005	0.806	0.155	0.049	0.011
TC	1.291	0.027	0.154	-0.027	-0.007	0.729
TG	0.055	0.002	0.909	0.180	0.044	0.020
UA	0.003	0.007	0.777	0.00	-0.017	0.481
药物史	2.590	0.017	0.410	0.721	0.048	0.009
既往史	2.728	0.017	0.366	0.702	0.049	0.012

变量	β值	OR值	95%可信区间	P值
BMI分级(kg/m²)
<18.5	-0.050	1.011	0.669~1.528	0.790
18.5~23.9	-	1.000	-	-
24.0~27.9	0.161	1.175	0.963~1.434	0.113
≥28.0	0.520	1.682	1.220~2.317	0.001
年龄	-0.012	0.990	0.983~0.997	<0.001
女性	0.581	1.827	1.496~2.233	<0.001